Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
Headline: Patent claim ruling requires appeals courts to accept district judges’ factual findings unless clearly erroneous, changing how patent disputes — including generic drug challenges — are reviewed on appeal.
Holding: The Court held that when a trial judge resolves subsidiary factual disputes during patent claim interpretation, an appeals court must review those factual findings only for clear error, while reviewing the ultimate legal construction de novo.
- Requires appeals courts to defer to trial judges’ factual findings unless clearly erroneous.
- Makes credibility determinations about expert evidence more binding on appeal.
- May send patent cases back to trial courts for reevaluation under the proper standard.
Summary
Background
A branded drug maker (Teva) sued a generic company (Sandoz) over a patent covering how the multiple sclerosis drug Copaxone is made. The patent described the drug’s active ingredient as having “a molecular weight of 5 to 9 kilodaltons,” but experts disagreed which of three scientific ways to calculate that weight the claim meant. The trial judge heard expert testimony, credited Teva’s expert, and held the claim definite. The Federal Circuit then reversed, treating the trial judge’s factual findings as legal and reviewing everything anew.
Reasoning
The Court answered whether appeals courts must defer to a trial judge’s subsidiary factual findings made during patent claim interpretation. It relied on Rule 52(a)(6), prior cases, and practical concerns about trial judges’ firsthand exposure to expert testimony. The Court said appeals courts must review subsidiary factual findings for clear error, but may still review the ultimate legal construction of patent claims de novo. It also explained that if the court relies only on the patent’s own text, review remains de novo.
Real world impact
The ruling changes appellate practice in patent cases nationwide. Appellate courts will generally accept trial judges’ credibility calls and factual findings about technical evidence unless clearly wrong. That can affect outcomes in suits over pharmaceutical patents and other technical inventions and may lead to remands for reconsideration under the correct standard.
Dissents or concurrances
Justice Thomas dissented, arguing claim construction is a legal question and urging de novo review; he warned deference could reduce uniformity across patent decisions.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?